Zoetis (ZTS) to Release Quarterly Earnings on Tuesday

Key Points

• Zoetis is expected to report its Q2 2025 earnings on August 5th, with analysts predicting earnings of $1.61 per share and revenue of $2.41 billion.
• The company has set its full-year 2025 guidance at 6.200-6.30 EPS, following a prior quarter where it reported a net margin of 27.12%.
• Zoetis announced a quarterly dividend of $0.50 per share, with a payout ratio of 35.91%, to be paid on September 3rd.

Zoetis (NYSE:ZTS - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect Zoetis to post earnings of $1.61 per share and revenue of $2.41 billion for the quarter. Zoetis has set its FY 2025 guidance at 6.200-6.30 EPS.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. Zoetis's quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.38 earnings per share. On average, analysts expect Zoetis to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Zoetis Price Performance

ZTS traded up $1.52 on Friday, reaching $147.31. 2,170,245 shares of the company's stock were exchanged, compared to its average volume of 3,053,582. The stock's fifty day moving average price is $158.82 and its 200-day moving average price is $160.58. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04. The stock has a market cap of $65.58 billion, a PE ratio of 26.44, a P/E/G ratio of 2.47 and a beta of 0.91. Zoetis has a twelve month low of $139.70 and a twelve month high of $200.33.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Zoetis's payout ratio is presently 35.91%.

Insider Activity

In other news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president owned 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.18% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ZTS. Brighton Jones LLC raised its stake in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after buying an additional 2,978 shares during the last quarter. Empowered Funds LLC raised its stake in Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company's stock valued at $1,859,000 after purchasing an additional 657 shares during the last quarter. Finally, Intech Investment Management LLC raised its stake in Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company's stock valued at $1,374,000 after purchasing an additional 1,224 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on ZTS shares. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. UBS Group lowered their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Piper Sandler increased their target price on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $204.63.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.